Rainer J. Klement; Reinhart A. Sweeney
Single arm with 6 participants: Our data lend support to the hypothesis that KDs administered as supportive measures during standard therapy are safe and might be helpful in preservation of muscle mass. There was consensus that the KD was satiating and weight loss occurred in all patients, although this was only significant in two patients. Our data indicate that weight loss was mainly due to fat mass loss with concurrent preservation of muscle mass. Overall quality of life remained fairly stable, and all subjects reported feeling good on the diet. Tumor regression occurred as expected in five patients with early stage disease
Alessandro Pinto; Alessio Bonucci; Elisa Maggi; Mariangela Corsi; Rita Businaro
Review: The few studies conducted on humans available so far are based on a pre/post design but without a reference control group and without randomization. Of particular interest were the RCTs that correlated the introduction of KD to an improvement of verbal receptive vocabulary and of reaction time in children affected by epilepsy, as well as an improvement in attention and memory in patients affected by multiple sclerosis. The results demonstrated causal evidence and stressed the need to increase the number of studies to demonstrate that 4:1 KD induces a cognitive improvement in neurological diseases
Jocelyn Tan-Shalaby; Roby Antony Thomas; Jennifer Carrick; Andrew D. Liman; Vida Almario Passero; Arisha Patel; Jenna Shields
Single arm prospective with 3 participants: Ketogenic diets in human lymphomas appears well tolerated and can improve symptoms, quality of life, and limit tumor growth. Ketogenic diets may reverse the weight loss seen in terminal cancer patients with cachexia
Jocelyn L. Tan-Shalaby; Jennifer Carrick; Krystal Edinger; Dana Genovese; Andrew D. Liman; Vida A. Passero; Rashmikant B. Shah
Single arm prospective with with 17 participants: Dysfunctional mitochondrial processes limit malignant cells ability to use energy from fatty acids and ketones. Animal studies using ketogenic diets for cancer show encouraging results. We tested the diet’s safety and feasibility in cancer patients across a broad variety of solid tumors.
Robert H. Lustig; Kathleen Mulligan; Susan M. Noworolsk;i Viva W. Tai; Michael J. Wen; Ayca Erkin‐Cakmak; Alejandro Gugliucci; Jean‐Marc Schwarz
Single arm prospective with 27 participants from 2 specific, at risk, ethnic groups: This study argues that the health detriments of sugar, and fructose specifically, are independent of its caloric value or effects on weight. Further studies will be required to determine whether sugar restriction alone can impact metabolic syndrome in adults and whether such effects are short‐lived or long‐term.
Ahmed M. A. Elsakka; Mohamed Abdel Bary; Eman Abdelzaher; Mostafa Elnaggar; Miriam Kalamian; Purna Mukherjee; Thomas N. Seyfried
Case Report: A press-pulse therapeutic strategy was implemented to target glucose and glutamine availability in a 38-year-old GBM patient using a modified SOC and KMT. As less than 20% of younger adults generally survive beyond 24 months with GBM, it is possible that the response observed in this case resulted in part from KMT and the modified SOC. The patient is now 40 years old and remains in excellent health with no noticeable neurological issues (Karnofsky Score, 100%) after 24 months of treatment.
Next Page »